Stockreport

Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia

Spectrum Pharmaceuticals, Inc.  (SPPI) 
Last spectrum pharmaceuticals, inc. earnings: 2/27 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.sppirx.com/investor-relations
PDF Submission based on results from two large, positive pivotal trials Both pivotal trials successfully met their primary endpoint and all [Read more]